Website: rexahn.com
SEC Filings: sec.gov
Press Releases: rexahn.com
Portfolio: rexahn.com
Lead drug candidates in Phase II trials:
Serdaxin® a best-in-class therapy for treating depression, and potentially Parkinson’s Disease and Alzheimer’s Disease. (April, 2010 Phase II protocol submitted to FDA for PD)
Zoraxel™ a first-in-class CNS-based therapy for treating sexual dysfunction. (March 2010 Phase IIb protocol submitted to FDA)
Archexin® a first-in-class AKT-inhibitor therapy for treating various cancers, such as pancreatic cancer, renal cell carcinoma (RCC), glioblastoma, and cancers of the ovary and stomach.
April 5, 2010 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of Parkinson’s disease (PD). |
